|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Carcinoma, Pancreatic Ductal | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Carcinoma | |||||
| Pancreatic Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Adenocarcinoma | |||||
| Carcinoma, Ductal | |||||
| Digestive System Diseases | |||||
| Digestive System Neoplasms | |||||
| Endocrine Gland Neoplasms | |||||
| Endocrine System Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Ductal, Lobular, and Medullary | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Pancreatic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| AG-013736 | |||||
| Gemcitabine | |||||
| placebo | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-Infective Agents | |||||
| Antimetabolites | |||||
| Antimetabolites, Antineoplastic | |||||
| Antineoplastic Agents | |||||
| Antiviral Agents | |||||
| Enzyme Inhibitors | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Radiation-Sensitizing Agents | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Pfizer | |||||